Fatigue evaluation in fingolimod treated patients: An observational study

Area of Science:

• Neurology
• Clinical Pharmacology

Background:

• Fatigue is a primary disabling symptom in Multiple Sclerosis (MS), significantly impacting patient quality of life.
• Fingolimod (Fg), an oral sphingosine 1-phosphate receptor modulator, is a disease-modifying treatment for MS.
• The specific effects of Fingolimod on MS-related fatigue remain largely uncharacterized.

Purpose of the Study:

• To evaluate the impact of Fingolimod on fatigue levels in Multiple Sclerosis patients within the initial six months of treatment.
• To assess changes in various fatigue measures following the commencement of Fingolimod therapy.

Main Methods:

• A prospective, open-label study was conducted in a real-world clinical setting.
• The primary outcome measure was the change in the Modified Fatigue Impact Scale (MFIS) from baseline to six months.
• Secondary outcomes included changes in MFIS subscales, Fatigue Severity Scale (FSS), and Visual Analog Scale of Fatigue (VAS-F).

Main Results:

• Fifty-four patients completed the six-month study.
• No statistically significant changes were observed in global MFIS, MFIS subscales, FSS, or VAS-F scores at six months.
• Patients with higher baseline fatigue (MFIS ≥38) had significantly higher EDSS scores but did not show different MFIS evolution compared to those with lower fatigue.

Conclusions:

• Fingolimod treatment demonstrated no significant impact on fatigue symptoms in Multiple Sclerosis patients after six months.
• The study suggests that Fingolimod may not be an effective treatment for alleviating fatigue in MS patients within this timeframe.